Johnson & Johnson halts rollout of vaccine in Europe amid US pause

More On:

COVID vaccine

White House didn’t know about J&J vaccine pause before anyone else

Trump bashes Biden administration for Johnson & Johnson vaccine pause

Johnson & Johnson vaccine probe will likely take ‘a matter of days,’ FDA says

Scheduled for a J&J vaccine in NY today? Here’s what you need to know

Johnson & Johnson announced Tuesday it is delaying the rollout of its COVID-19 vaccine in Europe amid concerns about potential blood clots in US recipients.

“We are aware of an extremely rare disorder involving people with blood clots in combination with low platelets in a small number of individuals who have received our COVID-19 vaccine,” the New Jersey-based drugmaker said in a statement.

“The United States Centers for Disease Control (CDC) and Food and Drug Administration (FDA) are reviewing data involving six reported U.S. cases out of more than 6.8 million doses administered,” J&J said.

“Out of an abundance of caution, the CDC and FDA have recommended a pause in the use of our vaccine,” the company noted — as US federal officials and states such New York announced they are yanking the shots until more research on the potential dangers is done.

“In addition, we have been reviewing these cases with European health authorities,” J&J said. “We have made the decision to proactively delay the rollout of our vaccine in Europe.”

The UK already ordered at least 30 million doses of the Johnson & Johnson single-dose immunization.

Share this article:

Source: Read Full Article